Interestingly, GLP-1/GIP coagonists have also been reported to have weight and glucose-lowering effects in obese T2D patients despite numerous studies supporting the notion that GIP promotes weight gain/obesity
Studies are currently examining the role of GLP-1s in conditions such as heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis, Alzheimers disease, Parkinsons disease, peripheral artery disease, diabetic kidney disease and cancer, and other pharmaceutical manufacturers are expected to apply for similar GLP-1 label expansions in the future
The two Phase 3 trials of the higher-dose version compared the efficacy and safety of once-weekly semaglutide 7.2mg to semaglutide 2.4mg over 72 weeks and showed that individuals with obesity, with or without type 2 diabetes, lost around 3 percent more of their body weight
Wegovy, a leading semaglutide injection, is administered weekly through a pre-filled pen device
Like we're just